The O
antipsychotic O
agent O
, O
remoxipride B
[ O
( B
S I
) I
- I
( I
- I
) I
- I
3 I
- I
bromo I
- I
N I
- I
[ I
( I
1 I
- I
ethyl I
- I
2 I
- I
pyrrolidinyl I
) I
methyl I
] I
- I
2 I
, I
6 I
- I
dimethoxybenz I
amide I
] O
has O
been O
associated O
with O
acquired O
aplastic O
anemia O
. O

Synthesis O
and O
preliminary O
pharmacological O
investigations O
of O
1 B
- I
( I
1 I
, I
2 I
- I
dihydro I
- I
2 I
- I
acenaphthylenyl I
) I
piperazine I
derivatives O
as O
potential O
atypical O
antipsychotic O
agents O
in O
mice O
. O

The O
synthesis O
and O
preliminary O
pharmacological O
evaluation O
of O
a O
series O
of O
potential O
atypical O
antipsychotic O
agents O
based O
on O
the O
structure O
of O
1 B
- I
( I
1 I
, I
2 I
- I
dihydro I
- I
2 I
- I
acenaphthylenyl I
) I
piperazine I
( O
7 O
) O
is O
described O
. O

Compound O
7e O
, O
5 B
- I
{ I
2 I
- I
[ I
4 I
- I
( I
1 I
, I
2 I
- I
dihydro I
- I
2 I
- I
acenaphthylenyl I
) I
piperazinyl I
] I
ethyl I
} I
- I
2 I
, I
3 I
- I
dihy I
dro I
- I
1H I
- I
indol I
- I
2 I
- I
one I
, O
from O
this O
series O
showed O
significant O
affinities O
at O
the O
5 O
- O
HT1A O
and O
5 O
- O
HT2A O
receptors O
and O
moderate O
affinity O
at O
the O
D2 O
receptor O
. O

BACKGROUND O
: O
Treatment O
with O
angiotensin B
- I
converting I
enzyme I
( I
ACE I
) I
inhibitors I
reduces O
mortality O
and O
morbidity O
in O
patients O
with O
chronic O
heart O
failure O
( O
CHF O
) O
, O
but O
most O
affected O
patients O
are O
not O
receiving O
these O
agents O
or O
are O
being O
treated O
with O
doses O
lower O
than O
those O
found O
to O
be O
efficacious O
in O
trials O
, O
primarily O
because O
of O
concerns O
about O
the O
safety O
and O
tolerability O
of O
these O
agents O
, O
especially O
at O
the O
recommended O
doses O
. O

Moreover O
, O
all O
adenosine B
receptor O
agonists O
: O
2 B
- I
p I
- I
( I
2 I
- I
carboxyethyl I
) I
phenethylamino I
- I
5 I
' I
- I
N I
- I
ethylcarboxamidoadenosine I
( O
CGS B
21680 I
) O
, O
A2A O
receptor O
agonist O
, O
N6 B
- I
cyclopentyladenosine I
( O
CPA B
) O
, O
A1 O
receptor O
agonist O
, O
and O
5 B
' I
- I
N I
- I
ethylcarboxamidoadenosine I
( O
NECA B
) O
, O
A2 O
/ O
A1 O
receptor O
agonist O
significantly O
and O
dose O
- O
dependently O
decreased O
cocaine B
- O
induced O
locomotor O
activity O
. O

The O
selective O
blockade O
of O
A2 O
adenosine B
receptor O
by O
DMPX B
( O
3 B
, I
7 I
- I
dimethyl I
- I
1 I
- I
propargylxanthine I
) O
significantly O
enhanced O
cocaine B
- O
induced O
locomotor O
activity O
of O
animals O
. O

In O
rodents O
, O
the O
effect O
of O
the O
beta B
- I
carboline I
derivative O
isopropyl B
- I
6 I
- I
benzyloxy I
- I
4 I
- I
methoxymethyl I
- I
beta I
- I
carboline I
- I
3 I
- I
carboxylate I
( O
abecarrnil B
) O
, O
a O
new O
ligand O
for O
benzodiazepine B
receptors O
possessing O
anxiolytic O
and O
anticonvulsant O
properties O
, O
was O
evaluated O
on O
the O
function O
of O
central O
gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
A O
receptor O
complex O
, O
both O
in O
vitro O
and O
in O
vivo O
. O

These O
effects O
were O
similar O
to O
those O
induced O
by O
diazepam B
, O
whereas O
the O
partial O
agonist O
Ro B
16 I
- I
6028 I
( O
tert B
- I
butyl I
- I
( I
S I
) I
- I
8 I
- I
bromo I
- I
11 I
, I
12 I
, I
13 I
, I
13a I
- I
tetrahydro I
- I
9 I
- I
oxo I
- I
9H I
- I
imidazo I
[ I
1 I
, I
5 I
- I
a I
] I
- I
pyrrolo I
- I
[ I
2 I
, I
1 I
- I
c I
] I
[ I
1 I
, I
4 I
] I
benzodiazepine I
- I
1 I
- I
carboxylate I
) O
showed O
very O
weak O
efficacy O
in O
these O
biochemical O
tests O
. O

Part O
A O
, O
for O
eight O
rats O
in O
each O
group O
brain O
injury O
was O
evaluated O
by O
staining O
tissue O
using O
2 B
, I
3 I
, I
5 I
- I
triphenyltetrazolium I
chloride I
and O
edema O
was O
evaluated O
by O
microgravimetry O
. O

Eslicarbazepine B
acetate I
( O
BIA B
2 I
- I
093 I
, O
S B
- I
( I
- I
) I
- I
10 I
- I
acetoxy I
- I
10 I
, I
11 I
- I
dihydro I
- I
5H I
- I
dibenzo I
/ I
b I
, I
f I
/ I
azepine I
- I
5 I
- I
carboxamide I
) O
is O
a O
novel O
antiepileptic O
drug O
, O
now O
in O
Phase O
III O
clinical O
trials O
, O
designed O
with O
the O
aim O
of O
improving O
efficacy O
and O
safety O
in O
comparison O
with O
the O
structurally O
related O
drugs O
carbamazepine B
( O
CBZ B
) O
and O
oxcarbazepine B
( O
OXC B
) O
. O

The O
lesions O
were O
placed O
via O
bilateral O
microinjections O
of O
30 O
nmol O
/ O
200 O
nl O
N B
- I
methyl I
- I
D I
- I
aspartic I
acid I
. O

The O
restimulation O
of O
this O
area O
with O
N B
- I
methyl I
- I
D I
- I
aspartic I
acid I
15 O
days O
postlesion O
failed O
to O
produce O
a O
pressor O
response O
. O

This O
study O
was O
designed O
to O
evaluate O
the O
alterations O
in O
offspring O
rat O
cerebellum O
induced O
by O
maternal O
exposure O
to O
carmustine B
- O
[ O
1 B
, I
3 I
- I
bis I
( I
2 I
- I
chloroethyl I
) I
- I
1 I
- I
nitrosoure I
] O
( O
BCNU B
) O
and O
to O
investigate O
the O
effects O
of O
exogenous O
melatonin B
upon O
cerebellar O
BCNU B
- O
induced O
cortical O
dysplasia O
, O
using O
histological O
and O
biochemical O
analyses O
. O

Reduced O
cardiotoxicity O
of O
doxorubicin B
given O
in O
the O
form O
of O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
conjugates O
: O
and O
experimental O
study O
in O
the O
rat O
. O

A O
rat O
model O
was O
used O
to O
evaluate O
the O
general O
acute O
toxicity O
and O
the O
late O
cardiotoxicity O
of O
4 O
mg O
/ O
kg O
doxorubicin B
( O
DOX B
) O
given O
either O
as O
free O
drug O
or O
in O
the O
form O
of O
three O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
copolymer O
conjugates O
. O

METHODS O
: O
Marmosets O
were O
administered O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridine I
( O
2 O
. O
0 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
for O
five O
days O
, O
resulting O
in O
stable O
parkinsonism O
. O

ACC B
- I
9653 I
, O
the O
disodium B
phosphate I
ester I
of O
3 B
- I
hydroxymethyl I
- I
5 I
, I
5 I
- I
diphenylhydantoin I
, O
is O
a O
prodrug O
of O
phenytoin B
with O
advantageous O
physicochemical O
properties O
. O

Application O
of O
an O
irreversible O
inhibitor O
of O
GABA B
transaminase O
, O
gamma B
- I
vinyl I
- I
GABA I
( O
D B
, I
L I
- I
4 I
- I
amino I
- I
hex I
- I
5 I
- I
enoic I
acid I
) O
, O
5 O
micrograms O
, O
into O
the O
SNR O
, O
bilaterally O
, O
suppressed O
the O
appearance O
of O
electrographic O
and O
behavioral O
seizures O
produced O
by O
pilocarpine B
, O
380 O
mg O
/ O
kg O
. O

On O
the O
antiarrhythmic O
activity O
of O
one O
N O
- O
substituted O
piperazine B
derivative O
of O
trans B
- I
2 I
- I
amino I
- I
3 I
- I
hydroxy I
- I
1 I
, I
2 I
, I
3 I
, I
4 I
- I
tetrahydroanaphthalene I
. O

The O
antiarrhythmic O
activity O
of O
the O
compound O
N B
- I
( I
trans I
- I
3 I
- I
hydroxy I
- I
1 I
, I
2 I
, I
3 I
, I
4 I
- I
tetrahydro I
- I
2 I
- I
naphthyl I
) I
- I
N I
- I
( I
3 I
- I
oxo I
- I
3 I
- I
phenyl I
- I
2 I
- I
methylpropyl I
) I
- I
piperazine I
hydrochloride I
, O
referred O
to O
as O
P11 B
, O
is O
studied O
on O
anaesthesized O
cats O
and O
Wistar O
albino O
rats O
, O
as O
well O
as O
on O
non O
- O
anaesthesized O
rabbits O
. O

Effect O
of O
doxorubicin B
on O
[ B
omega I
- I
I I
- I
131 I
] I
heptadecanoic I
acid I
myocardial O
scintigraphy O
and O
echocardiography O
in O
dogs O
. O

The O
effects O
of O
serial O
treatment O
with O
doxorubicin B
on O
dynamic O
myocardial O
scintigraphy O
with O
[ B
omega I
- I
I I
- I
131 I
] I
heptadecanoic I
acid I
( O
I B
- I
131 I
HA I
) O
, O
and O
on O
global O
left O
- O
ventricular O
function O
determined O
echocardiographically O
, O
were O
studied O
in O
a O
group O
of O
nine O
mongrel O
dogs O
. O

Angiotensin B
- I
converting I
enzyme I
( I
ACE I
) I
inhibitors I
, O
used O
to O
treat O
hypertension O
and O
congestive O
heart O
failure O
, O
were O
introduced O
in O
Europe O
in O
the O
middle O
of O
the O
eighties O
, O
and O
the O
use O
of O
these O
drugs O
has O
increased O
progressively O
. O

A O
significant O
reduction O
in O
urinary O
guanosine B
3 I
' I
, I
5 I
' I
- I
cyclic I
monophosphate I
( O
cGMP B
) O
excretion O
and O
a O
significant O
increase O
in O
renal O
cortical O
renin O
and O
endothelin O
- O
1 O
contents O
were O
also O
observed O
in O
GM B
- O
mediated O
nephropathy O
. O

Lamivudine B
is O
a O
novel O
2 B
' I
, I
3 I
' I
- I
dideoxy I
cytosine I
analogue O
that O
has O
potent O
inhibitory O
effects O
on O
hepatitis O
B O
virus O
replication O
in O
vitro O
and O
in O
vivo O
. O

Oral O
administration O
of O
2 B
, I
5 I
- I
di I
- I
O I
- I
acetyl I
- I
D I
- I
glucaro I
- I
1 I
, I
4 I
- I
6 I
, I
3 I
- I
dilactone I
protected O
rats O
against O
renal O
failure O
induced O
by O
kanamycin B
- O
dextran O
. O

